BioCentury | Aug 11, 2011
Targets & Mechanisms

ROS overload

...in a wide range of mouse models of cancer, 1 and the scientists have formed Canthera Therapeutics Inc....
...Lee and Michael Foley, director of the Chemical Biology Platform at the Broad Institute, formed Canthera...
...is nearly insoluble. We had a tough time doing the in vivo experiments," said Mandinova. Canthera...
BioCentury | Aug 11, 2011
Distillery Therapeutics

Indication: Cancer

...doi:10.1038/scibx.2011.876 Published online Aug. 11, 2011 Patent application filed by Massachusetts General Hospital; licensed by Canthera Therapeutics Inc....
Items per page:
1 - 2 of 2
BioCentury | Aug 11, 2011
Targets & Mechanisms

ROS overload

...in a wide range of mouse models of cancer, 1 and the scientists have formed Canthera Therapeutics Inc....
...Lee and Michael Foley, director of the Chemical Biology Platform at the Broad Institute, formed Canthera...
...is nearly insoluble. We had a tough time doing the in vivo experiments," said Mandinova. Canthera...
BioCentury | Aug 11, 2011
Distillery Therapeutics

Indication: Cancer

...doi:10.1038/scibx.2011.876 Published online Aug. 11, 2011 Patent application filed by Massachusetts General Hospital; licensed by Canthera Therapeutics Inc....
Items per page:
1 - 2 of 2